Current Report Filing (8-k)
November 30 2020 - 9:23AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) November 30, 2020
Citius
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction of incorporation)
333-206903
|
|
27-3425913
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|
11
Commerce Drive, 1st Floor, Cranford, NJ
|
|
07016
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code (908) 967-6677
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange
on which registered
|
Common
stock, $0.001 par value
|
|
CTXR
|
|
The
Nasdaq Capital Market
|
Warrants
to purchase common stock
|
|
CTXRW
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On November 30, 2020, Citius Pharmaceuticals,
Inc. issued a press release announcing the results of a Boston Analytical study that demonstrated that Mino-Lok eradicates S. aureus
biofilm more effectively and expeditiously than its components. A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CITIUS PHARMACEUTICALS, INC.
|
|
|
Date: November 30 2020
|
/s/ Myron Holubiak
|
|
Myron Holubiak
|
|
President and Chief Executive Officer
|
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Apr 2023 to Apr 2024